Company / Cash & Equivalents
Tvardi Therapeutics, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$37.9M
FY2024
5-year range
$13.5M / $63.7M
FY2020-FY2024
Trend
-26.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $9M in FY2017 to $64M in FY2022.
Based on SEC 10-K filings.
$38M in FY2024 with a 5-year CAGR of +15.7%.
Declined from $64M to $38M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +41.2%
- 5-Year CAGR
- +15.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +15.7%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 26.8% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $37.9M | -26.8% |
| FY2023 | $51.8M | -18.8% |
| FY2022 | $63.7M | +373.8% |
| FY2021 | $13.5M | -57.5% |
| FY2020 | $31.7M | +73.1% |
| FY2019 | $18.3M | +21.4% |
| FY2018 | $15.1M | +60.6% |
| FY2017 | $9.4M | -82.2% |
| FY2016 | $52.7M | +326.2% |
| FY2015 | $12.4M | +1006.3% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026